Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Evolutionary Pathways to Persistence of Highly Fit and Resistant Hepatitis C Virus Protease Inhibitor Escape Variants

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

DOI

  1. Pathogenesis, MicroRNA-122 Gene-Regulation, and Protective Immune Responses After Acute Equine Hepacivirus Infection

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Letter to the Editor: Glucocorticosteroids for Alcohol-Associated Hepatitis

    Publikation: Bidrag til tidsskriftLetterForskningpeer review

  3. PNPLA3 genotype and risk of liver and all-cause mortality

    Publikation: Bidrag til tidsskriftLederForskningpeer review

  4. High Risk of Fatty Liver Disease Amplifies the Alanine Transaminase-Lowering Effect of a HSD17B13 Variant

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Neutralisation titres against SARS-CoV-2 are sustained 6 months after onset of symptoms in individuals with mild COVID-19

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Pathogenesis, MicroRNA-122 Gene-Regulation, and Protective Immune Responses After Acute Equine Hepacivirus Infection

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Vaccines against hepatitis C: a travel into neutralisation space

    Publikation: Bidrag til tidsskriftKommentar/debatForskningpeer review

Vis graf over relationer

Protease inhibitors (PIs) are important components of treatment regimens for patients with chronic hepatitis C virus (HCV) infection. However, emergence and persistence of antiviral resistance could reduce their efficacy. Thus, defining resistance determinants is highly relevant for efforts to control HCV. Here, we investigated patterns of PI resistance associated substitutions (RASs) for the major HCV genotypes and viral determinants for persistence of key RASs. We identified protease position 156 as RAS hotspot for genotype 1-4, but not 5 and 6 escape variants by resistance profiling using PIs grazoprevir and paritaprevir in infectious cell culture systems. However, except for genotype 3, engineered 156-RASs were not maintained. For genotypes 1 and 2, persistence of 156-RASs depended on genome-wide substitution networks, co-selected under continued PI treatment and identified by next generation sequencing with substitution linkage and haplotype reconstruction. Persistence of A156T for genotype 1 relied on compensatory substitutions increasing replication and assembly. For genotype 2, initial selection of A156V facilitated transition to 156L, persisting without compensatory substitutions. The developed genotype 1, 2, and 3 variants with persistent 156-RASs had exceptionally high fitness and resistance to grazoprevir, paritaprevir, glecaprevir and voxilaprevir. A156T dominated in genotype 1 glecaprevir and voxilaprevir escape variants, and pre-existing A156T facilitated genotype 1 escape from clinically relevant combination treatments with grazoprevir/elbasvir and glecaprevir/pibrentasvir. In genotype 1 infected patients with treatment failure and 156-RASs we observed genome-wide selection of substitutions under treatment. CONCLUSIONS: Comprehensive PI resistance profiling for HCV genotypes 1-6 revealed 156-RASs as key determinants of high-level resistance across clinically relevant PIs. We obtained in vitro proof-of-concept for persistence of highly fit genotype 1-3 156-variants, which might pose a threat to clinically relevant combination treatments. This article is protected by copyright. All rights reserved.

OriginalsprogEngelsk
TidsskriftHepatology (Baltimore, Md.)
Vol/bind70
Udgave nummer3
Sider (fra-til)771-787
Antal sider17
ISSN0270-9139
DOI
StatusUdgivet - sep. 2019

ID: 56978088